InvestSMART

Tryptamine Therapeutics Limited (ASX: TYP) - Announcements

Current share price for TYP : $0.034 0.002 (5.56%)+

ASX company news and announcements for Tryptamine Therapeutics Limited (TYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Tryptamine Therapeutics Limited (TYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Tryptamine Therapeutics Limited (TYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Tryptamine Therapeutics Limited (TYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Cleansing Notice 18 Nov 2025 10:21AM $0.035 $0.034 fallen by 2.86%
- Application for quotation of securities - TYP 18 Nov 2025 10:10AM $0.035 $0.034 fallen by 2.86%
- BED trial accelerates - enrolment grows, dosing in two weeks 18 Nov 2025 8:55AM $0.036 $0.034 fallen by 5.56%
- Change of Registered Office & Principal Place of Business 14 Nov 2025 9:43AM $0.036 $0.034 fallen by 5.56%
- Results of AGM 13 Nov 2025 4:54PM $0.036 $0.034 fallen by 5.56%
- Notification of cessation of securities - TYP 11 Nov 2025 3:42PM $0.038 $0.034 fallen by 10.53%
- September 2025 Quarterly Activities Report Correction 7 Nov 2025 2:32PM $0.036 $0.034 fallen by 5.56%
- Application for quotation of securities - TYP 5 Nov 2025 1:42PM $0.036 $0.034 fallen by 5.56%
- Proposed issue of securities - TYP 5 Nov 2025 9:38AM $0.038 $0.034 fallen by 10.53%
- Proposed issue of securities - TYP 5 Nov 2025 9:38AM $0.038 $0.034 fallen by 10.53%
- $6.1m in new funding to accelerate clinical development 5 Nov 2025 9:38AM $0.038 $0.034 fallen by 10.53%
- Trading Halt 3 Nov 2025 9:22AM $0.038 $0.034 fallen by 10.53%
- Quarterly Activities Report and Appendix 4C 31 Oct 2025 6:19PM $0.038 $0.034 fallen by 10.53%
- Addendum to Notice of Meeting 24 Oct 2025 11:02AM $0.037 $0.034 fallen by 8.11%
- Microcap Investment Conference Investor Presentation 21 Oct 2025 8:40AM $0.036 $0.034 fallen by 5.56%
- First patient enrolled in Binge Eating Disorder Trial 14 Oct 2025 9:14AM $0.038 $0.034 fallen by 10.53%
- 2025 AGM Notice of Meeting, Letter of Access and Proxy 13 Oct 2025 9:18AM $0.039 $0.034 fallen by 12.82%
- Notification of cessation of securities - TYP 29 Sep 2025 3:48PM $0.041 $0.034 fallen by 17.07%
- Notification of Date of 2025 AGM 16 Sep 2025 9:26AM $0.032 $0.034 risen by 6.25%
- Neuropsychiatric Drug Development Summit Presentation 9 Sep 2025 3:17PM $0.032 $0.034 risen by 7.94%
- Application for quotation of securities - TYP 8 Sep 2025 1:23PM $0.033 $0.034 risen by 3.03%
- Appendix 4G and Corporate Governance Statement 29 Aug 2025 9:05AM $0.032 $0.034 risen by 6.25%
- Appendix 4E and 2025 Annual Report 29 Aug 2025 8:52AM $0.032 $0.034 risen by 6.25%
- Proposed issue of securities - TYP 21 Aug 2025 9:30AM $0.033 $0.034 risen by 3.03%
- Landmark EEG Biomarker Agreement for Precision Psychiatry 21 Aug 2025 8:58AM $0.033 $0.034 risen by 3.03%

1 - 25 of 144 results

Page 1 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.